NSG 5240 Advanced Pharmacology final exam Most
Frequently Tested QUESTIONs & Correct Answers
2026/2027
QUESTION 1
A patient taking oral anticoagulation with warfarin is concurrently
prescribed rifampin for latent tuberculosis. Two weeks later, the
patient's International Normalized Ratio (INR) drops below therapeutic
range, resulting in a thrombotic event. What pharmacokinetic
mechanism explains this clinical outcome?
• A. Rifampin is a potent hepatic cytochrome P450 enzyme inducer
that accelerates the metabolism and clearance of warfarin,
decreasing its systemic concentration.
• B. Rifampin binds directly to warfarin in the gastrointestinal tract,
preventing its absorption.
• C. Rifampin inhibits renal excretion of warfarin, causing toxicity.
• D. Rifampin acts as a vitamin K antagonist, neutralizing warfarin.
Correct Answer: A. Rifampin is a potent hepatic cytochrome P450
enzyme inducer that accelerates the metabolism and clearance of
warfarin, decreasing its systemic concentration.
Detailed Rationale: Rifampin is a powerful inducer of hepatic CYP
enzymes (including CYP2C9 and CYP3A4, which metabolize warfarin).
Induction increases the synthesis of these enzymes, leading to rapid
,breakdown of warfarin, lower plasma levels, and a subtherapeutic INR,
risking thrombosis.
QUESTION 2
How does a competitive antagonist differ from a non-competitive
antagonist in terms of receptor binding and the effect on a agonist
dose-response curve?
• A. A competitive antagonist binds irreversibly to the receptor,
reducing the maximal efficacy of the agonist.
• B. A competitive antagonist binds reversibly to the active site,
shifting the agonist dose-response curve to the right without
reducing maximal efficacy; a non-competitive antagonist reduces
maximal efficacy.
• C. A competitive antagonist increases the potency of the agonist.
• D. A non-competitive antagonist can always be overcome by
adding more agonist.
Correct Answer: B. A competitive antagonist binds reversibly to the
active site, shifting the agonist dose-response curve to the right without
reducing maximal efficacy; a non-competitive antagonist reduces
maximal efficacy.
Detailed Rationale: Competitive antagonists compete with agonists for
the same receptor binding site in a reversible manner. High
concentrations of the agonist can overcome this blockade, shifting the
curve rightward. Non-competitive antagonists bind irreversibly or to an
allosteric site, reducing the total number of functional receptors
available, thereby suppressing maximal efficacy (𝐸𝑚𝑎𝑥 ).
,QUESTION 3
A clinician evaluates the pharmacokinetics of a newly developed
intravenous antibiotic versus its oral formulation. The oral formulation
has a bioavailability of 40%. What does a bioavailability of 40% signify?
• A. 40% of the administered dose is excreted unchanged in the
urine.
• B. Only 40% of the oral dose reaches the systemic circulation
unchanged after accounting for incomplete absorption and first-
pass hepatic metabolism.
• C. The drug is 40% bound to plasma proteins.
• D. 60% of the drug is actively metabolized by renal tubular
secretion.
Correct Answer: B. Only 40% of the oral dose reaches the systemic
circulation unchanged after accounting for incomplete absorption and
first-pass hepatic metabolism.
Detailed Rationale: Bioavailability (𝐹) measures the fraction of an
administered drug that reaches systemic circulation in an active form.
An oral bioavailability of 40% indicates that 60% of the drug is lost due
to incomplete gastrointestinal absorption and first-pass hepatic
metabolism before reaching the general circulation.
QUESTION 4
A patient with a documented history of severe asthma is evaluated for
hypertension. Why is the selection of a non-selective beta-blocker (such
as propranolol) contraindicated in this patient?
• A. It stimulates histamine release from mast cells.
, • B. Blockade of beta-2 adrenergic receptors in bronchial smooth
muscle can precipitate severe bronchospasm.
• C. It causes profound hypoglycemia that cannot be treated with
glucagon.
• D. It directly paralyates the diaphragm.
Correct Answer: B. Blockade of beta-2 adrenergic receptors in bronchial
smooth muscle can precipitate severe bronchospasm.
Detailed Rationale: Non-selective beta-blockers block both beta-1
(cardiac) and beta-2 (bronchial and vascular smooth muscle) receptors.
Blocking beta-2 receptors removes sympathetic bronchodilation, which
can trigger severe, life-threatening bronchoconstriction in patients with
reactive airway diseases like asthma or COPD.
QUESTION 5
A patient initiated on lisinopril for hypertension complains of a
persistent, dry, hacking cough. What is the biochemical mechanism
responsible for this adverse effect?
• A. Accumulation of bradykinin and substance P in the pulmonary
tree due to inhibition of angiotensin-converting enzyme (kininase
II)
• B. Direct chemical irritation of the laryngeal mucosa by the tablet
coating
• C. Stimulation of peripheral histamine receptors
• D. Downregulation of pulmonary surfactant production
Frequently Tested QUESTIONs & Correct Answers
2026/2027
QUESTION 1
A patient taking oral anticoagulation with warfarin is concurrently
prescribed rifampin for latent tuberculosis. Two weeks later, the
patient's International Normalized Ratio (INR) drops below therapeutic
range, resulting in a thrombotic event. What pharmacokinetic
mechanism explains this clinical outcome?
• A. Rifampin is a potent hepatic cytochrome P450 enzyme inducer
that accelerates the metabolism and clearance of warfarin,
decreasing its systemic concentration.
• B. Rifampin binds directly to warfarin in the gastrointestinal tract,
preventing its absorption.
• C. Rifampin inhibits renal excretion of warfarin, causing toxicity.
• D. Rifampin acts as a vitamin K antagonist, neutralizing warfarin.
Correct Answer: A. Rifampin is a potent hepatic cytochrome P450
enzyme inducer that accelerates the metabolism and clearance of
warfarin, decreasing its systemic concentration.
Detailed Rationale: Rifampin is a powerful inducer of hepatic CYP
enzymes (including CYP2C9 and CYP3A4, which metabolize warfarin).
Induction increases the synthesis of these enzymes, leading to rapid
,breakdown of warfarin, lower plasma levels, and a subtherapeutic INR,
risking thrombosis.
QUESTION 2
How does a competitive antagonist differ from a non-competitive
antagonist in terms of receptor binding and the effect on a agonist
dose-response curve?
• A. A competitive antagonist binds irreversibly to the receptor,
reducing the maximal efficacy of the agonist.
• B. A competitive antagonist binds reversibly to the active site,
shifting the agonist dose-response curve to the right without
reducing maximal efficacy; a non-competitive antagonist reduces
maximal efficacy.
• C. A competitive antagonist increases the potency of the agonist.
• D. A non-competitive antagonist can always be overcome by
adding more agonist.
Correct Answer: B. A competitive antagonist binds reversibly to the
active site, shifting the agonist dose-response curve to the right without
reducing maximal efficacy; a non-competitive antagonist reduces
maximal efficacy.
Detailed Rationale: Competitive antagonists compete with agonists for
the same receptor binding site in a reversible manner. High
concentrations of the agonist can overcome this blockade, shifting the
curve rightward. Non-competitive antagonists bind irreversibly or to an
allosteric site, reducing the total number of functional receptors
available, thereby suppressing maximal efficacy (𝐸𝑚𝑎𝑥 ).
,QUESTION 3
A clinician evaluates the pharmacokinetics of a newly developed
intravenous antibiotic versus its oral formulation. The oral formulation
has a bioavailability of 40%. What does a bioavailability of 40% signify?
• A. 40% of the administered dose is excreted unchanged in the
urine.
• B. Only 40% of the oral dose reaches the systemic circulation
unchanged after accounting for incomplete absorption and first-
pass hepatic metabolism.
• C. The drug is 40% bound to plasma proteins.
• D. 60% of the drug is actively metabolized by renal tubular
secretion.
Correct Answer: B. Only 40% of the oral dose reaches the systemic
circulation unchanged after accounting for incomplete absorption and
first-pass hepatic metabolism.
Detailed Rationale: Bioavailability (𝐹) measures the fraction of an
administered drug that reaches systemic circulation in an active form.
An oral bioavailability of 40% indicates that 60% of the drug is lost due
to incomplete gastrointestinal absorption and first-pass hepatic
metabolism before reaching the general circulation.
QUESTION 4
A patient with a documented history of severe asthma is evaluated for
hypertension. Why is the selection of a non-selective beta-blocker (such
as propranolol) contraindicated in this patient?
• A. It stimulates histamine release from mast cells.
, • B. Blockade of beta-2 adrenergic receptors in bronchial smooth
muscle can precipitate severe bronchospasm.
• C. It causes profound hypoglycemia that cannot be treated with
glucagon.
• D. It directly paralyates the diaphragm.
Correct Answer: B. Blockade of beta-2 adrenergic receptors in bronchial
smooth muscle can precipitate severe bronchospasm.
Detailed Rationale: Non-selective beta-blockers block both beta-1
(cardiac) and beta-2 (bronchial and vascular smooth muscle) receptors.
Blocking beta-2 receptors removes sympathetic bronchodilation, which
can trigger severe, life-threatening bronchoconstriction in patients with
reactive airway diseases like asthma or COPD.
QUESTION 5
A patient initiated on lisinopril for hypertension complains of a
persistent, dry, hacking cough. What is the biochemical mechanism
responsible for this adverse effect?
• A. Accumulation of bradykinin and substance P in the pulmonary
tree due to inhibition of angiotensin-converting enzyme (kininase
II)
• B. Direct chemical irritation of the laryngeal mucosa by the tablet
coating
• C. Stimulation of peripheral histamine receptors
• D. Downregulation of pulmonary surfactant production
